Lower $1,000 Pill Price? We'd Love It, Says Express Scripts
(Bloomberg) -- More than two years after Express Scripts Holding Co. helped kick off a debate over U.S. pharmaceutical costs by starting a price war over Gilead Sciences Inc.’s expensive hepatitis C pills, the companies are fighting again.
Last week, a senior Gilead executive said that pharmacy benefit managers like Express Scripts profit from high drug prices because it lets them take a bigger slice of the discounts they negotiate for clients. PBMs wouldn’t even let drugmakers cut prices if they asked, said the executive.
On Monday, Express Scripts wrote Gilead’s CEO and dared him to go ahead.
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- FibroScan® Understanding The Results
- Is There A Natural Way To Improve Liver Fibrosis?
- Staging Cirrhosis